Melanoma immunotherapy has a critical limitation: 40 to 60% of patients don’t respond. Arielle Elkrief, MD, discusses an innovative approach targeting the gut microbiome. By using fecal microbiota…
Muneeb Shah MD, and Luke Maxfield, MD, break down the essentials of skin cancer, explaining the causes, symptoms, and treatments of basal cell carcinoma, squamous cell carcinoma, and…
A preliminary clinical study looking at previously untreated metastatic melanoma showed promising results when treating with the combination of an IL-2 signaling agonist and nivolumab. Primary trial objectives…
Early data from the phase III CheckMate 067 trial, reported in September 2017, showed that patients with advanced melanoma treated with nivolumab, with or without ipilimumab, maintained their quality…
A retrospective study’s multivariate analysis suggests that in the treatment of early invasive melanoma, the use of Mohs micrographic surgery is associated with better outcomes when compared with…
Despite an abundance of preclinical evidence supporting the treatment strategy of combining an IDO1 inhibitor with anti-PD-1/PD-L1 immunotherapy, the results of a recent clinical trial were unable to confirm…
With the growth of immunotherapies in recent years as an effective melanoma treatment option, there are still patients who do not respond well to immunotherapies. Hildur Helgadottir, MD,…
